Jam

ACI Worldwide launched ACI Connetic, a new cloud-native payment hub integrating various global payment networks. This platform brings together account-to-account, card payments, and AI-driven fraud prevention, allowing financial institutions to modernize payment infrastructures. Designed for scalability and resilience, ACI Connetic aims to streamline operations, reduce costs, and accelerate innovation. The solution, which is gaining traction in Europe and the US, will be showcased at EBAday 2025.

JOYY Inc. reported strong Q1 2025 results, showcasing revenue of $494.4 million. Non-livestreaming revenue surged 25.3% year-over-year, representing 24.9% of total revenue. Significant growth was observed in both GAAP and non-GAAP operating profit, with operational efficiency reflected in operating margins. The company also returned value to shareholders through dividends and share repurchases, and is focusing on diversification through core livestreaming and the expanding BIGO Ads platform.

CreateAI launched its AI-powered anime platform, Animon.ai, in Korea, following its Japan debut. The platform features text-to-video generation, expanded language support (including Traditional Chinese and Korean), and a subscription model for unlimited content creation. Developed with leading Japanese animators, Animon.ai aims to empower creators with user-friendly, professional-grade tools and a straightforward “text → image → video” workflow, with plans for further feature and language expansion.

JOYY Inc. (NASDAQ: JOYY) reported mixed Q1 2025 results, with lower overall revenue but improved profitability driven by diversification and cost management. Non-livestreaming revenue surged. The company returned capital to shareholders via dividends and share repurchases. User metrics showed declines, but net cash remains strong. JOYY forecasts revenue growth for Q2, emphasizing its strategic shift and diversified business model, particularly in advertising.

Silvercorp Metals Inc. (TSX: SVM; NYSE American: SVM) declared a semi-annual cash dividend of US$0.0125 per common share, payable by June 26, 2025, to shareholders of record as of June 6. The Canadian precious metals producer highlighted the dividend’s eligibility for favorable tax treatment under Canadian regulations, reflecting confidence in its operational stability amid volatile silver prices (US$28–34/oz this quarter). With 14 consecutive years of positive cash flow, Silvercorp has distributed over US$145 million to shareholders since 2011 through dividends and buybacks. The company’s shares rose 18% YTD, outperforming peers, while its strategy emphasizes low-cost mining, exploration, strategic acquisitions, and ESG integration across global operations.

Alvotech (NASDAQ: ALVO) will hold its 2025 Annual General Meeting on June 25 in Reykjavik, with virtual access available. Shareholders will review governance updates, financial results, and strategies to bolster its position in the biosimilars market, projected to yield $50 billion in global savings by 2027. Key discussions include expanding its biosimilar pipeline, regulatory progress in the U.S. and Europe, and addressing pricing challenges and patent cliffs. Analysts highlight priorities like commercial partnerships, scalable manufacturing, and differentiation in immunology and oncology. The meeting may signal strategic shifts as Alvotech navigates evolving FDA regulations and leverages biosimilars to counter pharmaceutical revenue declines, emphasizing speed-to-market and cost efficiency.

HyOrc Corporation (OTC: ASPZ) is expanding globally with hydrogen rail systems, green methanol production, and modular off-grid energy solutions. Its hybrid technology merges hydrogen combustion with organic Rankine cycle turbines, offering diesel alternatives at cost parity without subsidies. Key strengths include a diversified project pipeline, focus on decarbonization markets (EU/UK), and planned OTCQB uplisting. Challenges encompass scaling risks, unproven technical differentiation, and undisclosed partnership details. Analysts highlight potential supply chain disruption through containerized systems, while HyOrc targets rail operators and industries needing emissions-compliant solutions. The company emphasizes an asset-light, licensing-based model amid tightening global emissions regulations.

Y-mAbs Therapeutics presented Phase 1 Trial 1001 data for its GD2-SADA PRIT therapy at the Neuroblastoma Research Meeting, targeting recurrent/refractory GD2-positive solid tumors (neuroblastoma, lung cancer, sarcoma, melanoma). The two-step approach combines non-radioactive GD2-SADA proteins with Lutetium-177 to selectively irradiate tumors. Following Part A dose optimization, preliminary safety/efficacy results will be disclosed May 28th. If proven effective, this precision radiotherapy platform could address high-unmet needs across oncology markets, positioning YMAB for potential partnerships in the $6.8B radiopharma sector.

Atico Mining secured a 30-year concession for Colombia’s El Roble copper-gold mine, stabilizing operations until 2055 and releasing $10M worth of pledged copper concentrate for immediate liquidity. The deal resolves a $12M arbitration liability, with $3M paid and $10.7M deferred to 2025–2026, aligned with projected cash flows. It transitions regulatory terms to modern mining codes but adds community development and state compensation costs. CEO Ganoza emphasized the concession’s role in shifting focus to growth and exploration. Risks include copper price volatility and inflation-adjusted settlement increases. The mine remains central to Atico’s revenue amid Colombia’s evolving mining policies.

COSCIENS Biopharma faces activist pressure as investors Goodwood Fund and Puccetti Funds Management nominate six board directors, signaling a push for strategic changes. The firm, known for plant-based innovations in skincare (e.g., Aveeno’s oat compounds) and diagnostics like macimorelin, is evaluating the proposal amid scrutiny over its clinical trial pace, particularly for its cholesterol drug candidate. Balancing cosmeceutical growth with pharmaceutical ambitions, COSCIENS confronts investor demands for accelerated commercialization and governance reforms. Challenges include trial uncertainties for its growth hormone diagnostic and market pressures, with leadership decisions likely to shape its trajectory in competitive biopharma markets.